The puromycin-induced stimulation of [3H]dihydrorosaramicin binding is due to a twofold increase in affinity of the macrolide antibiotic, with no change in the number of binding sites. Conversely, the binding of [3H]puromycin (A site) is stimulated by rosaramicin. The synergistic effect observed between the two antibiotics can be explained by a conformational change with positive effect, which occurs at the level of their binding sites.Various effectors of [3H]dihydrorosaramicin binding have been tested. Adenosine and dimethyladenosine stimulate the binding; phenylalanine, uridine and gougerotin (A site) have no effect whereas AMP, ADP, ATP, GTP, puromycin 5'-phosphate and lincomycin (P site) are inhibitors. These results point to the importance of the purine moiety in the stimulatory effect and of the phosphate function in reversing this effect. I t is concluded that rosaramicin binds to the ribosomal P site and that the synergism observed between rosaramicin and puromycin may be related to interactions between the A and P sites.The mechanism of action of macrolide antibiotics has been a matter of controversy and we have only scant knowledge of the localization of macrolide binding sites. Recent results have shown that erythromycin, carbomycin and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyltRNA from Escherichiu coliribosomes [I], suggesting that these three macrolides bind to the 50-S ribosomal subunit blocking the P site. The binding of erythromycin, a 14-membered macrolide. has been widely studied [2]. Among the 16-membered macrolides, rosaramicin displays fairly good antibacterial properties. In a previous paper [3], we have shown that its derivative 20,20-[3H]dihydrorosaramicin binds reversibly to tightly coupled 70-S E. coli ribosomes, with one high-affinity binding site (n = 1, Kd = 0.2pM) and multiple low-affinity binding sites. Moreover, the dihydro derivative can be used to evaluate the binding of the parent compound. In our search for effectors of [3H]dihydrorosaramicin binding, we have found [4] that it is inhibited by other macrolides, poorly affected by tobramycin and chloramphenicol and considerably enhanced by puromycin. The level of binding stimulation (100 %) was strong enough to prompt us to develop further studies.In the present paper, we analyse the influence of puromycin, of structurally related molecules and of drugs acting on the P or A sites, on the [3H]dihydrorosaramicin binding to E. coli bacterial ribosomes.
MATERIALS A N D METHODS
ChemicalsRosaramicin was a gift of Unilabo (France); 20,20-[3H]dihydrorosaramicin was synthesized in our laboratory [3] (850 Ci/mol). Puromycin and phenylalanine were from Serva, [8(n)-3H]puromycin from CEA (500 Ci/mol), adenosine, dimethyladenosine, lincomycin, gougerotin and puromycin 5'-monophosphate from Sigma, ATP from Boehringer, GTP from Fluka, and uridine from Janssen.Buffer A contained 20mM Tris/HC1 (pH7.6), 6 m M Mg(OAc),, 60mM NH,Cl. Buffer B contained 10mM Tris/HCl (pH 7.6), 10 mM Mg(OAc),, 100 mM NH,Cl.
Acti...